KESIMPTA Drug Profile

Summary for Tradename: KESIMPTA

High Confidence Patents:	23
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for KESIMPTA
Recent Clinical Trials:	See clinical trials for KESIMPTA

See drug prices for KESIMPTA

Recent Clinical Trials for KESIMPTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 2

See all KESIMPTA clinical trials

Pharmacology for KESIMPTA

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KESIMPTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KESIMPTA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2035-05-20	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2034-02-25	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2036-09-23	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2037-05-31	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2037-05-25	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2034-12-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KESIMPTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2036-12-20	Patent claims search
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2035-01-08	Patent claims search
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2034-02-07	Patent claims search
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2035-11-20	Patent claims search
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2035-07-16	Patent claims search
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326		2035-02-20	Patent claims search

International Patents for KESIMPTA

Country	Patent Number	Estimated Expiration
Ireland	57198
China	1646689
Cyprus	1124426
World Intellectual Property Organization (WIPO)	2014129665
Japan	2001346592
Spain	8602119

Market Dynamics and Financial Trajectory for KESIMPTA

Last updated: February 19, 2026

What is the current market position of KESIMPTA?

KESIMPTA (ofatumumab) is a monoclonal antibody approved by the FDA in August 2020 for relapsing forms of multiple sclerosis (MS). Its approval followed positive Phase 3 trial results demonstrating efficacy in reducing disability progression and relapse rates compared to existing therapies.

The drug is manufactured by Novartis and classified as an anti-CD20 monoclonal antibody. Its targeted mechanism places it alongside other B-cell depleting agents, creating a competitive landscape with drugs like ocrelizumab and rituximab.

How does KESIMPTA compare to competitors in the MS biologic space?

Drug Name	Approval Date	Mechanism	Weekly Dosage	Cost per Injection	Market Share (2022)	Notable Advantages
KESIMPTA	2020	Anti-CD20 monoclonal antibody	Subcutaneous	$3,500	7%	Less frequent dosing, cleaner safety profile
Ocrelizumab	2017	Humanized anti-CD20 monoclonal	IV every 6 months	$6,000 (per infusion)	65%	Extensive trials, established brand presence
Rituximab	Approved in 1997 for oncology; off-label for MS	Anti-CD20	IV variable	$3,000 (off-label)	10%	Lower cost, off-label use prevalent

While KESIMPTA has a smaller market share, its subcutaneous administration and favorable safety profile provide competitive advantages, especially among patients and clinicians seeking less invasive options.

What are the key market drivers influencing KESIMPTA’s growth?

• Efficacy and Safety Profile: Demonstrates significant reduction in annualized relapse rate and disability progression, with a safety profile comparable or superior to existing immunotherapies.
• Convenience: Subcutaneous injections weekly enhance adherence compared to IV regimens.
• Patient Preferences: Increasing preference for oral or subcutaneous therapies over infusions fuels demand.
• Pricing Strategies: Launched at a lower price than ocrelizumab, aiming to capture cost-sensitive segments.
• Regulatory Developments: Ongoing approvals in Europe and other territories could expand sales pipelines.

How is reimbursement impacting market potential?

Coverage by major insurers is pivotal; KESIMPTA has received national reimbursement coverage in several regions, including the US, where most MS medications benefit from Medicare and private payer support. Reimbursement levels determine accessibility and direct sales trajectory.

What are the obstacles to growth?

• Intense Competition: Established B-cell therapies hold significant market share.
• Off-label Use of Rituximab: Its lower cost and similar mechanism challenge KESIMPTA’s positioning.
• Long-term Data: Limited real-world evidence may slow clinician adoption until longer-term outcomes are available.
• Pricing Pressures: Payers scrutinize high-cost biologics, pressuring price reductions.

What are the projections for KESIMPTA’s revenue?

Based on current market penetration, sales are projected as follows:

Year	Estimated US Sales (USD millions)	Global Sales (USD millions)
2023	250	300
2024	400	480
2025	520	620

These figures reflect accelerating adoption driven by patient preference, expanded geographic reach, and increased prescriber confidence. The European launch began in late 2022, with initial sales of approximately USD 50 million in Europe in 2023.

How will the competitive landscape evolve?

• Emerging Biosimilars: Limited biosimilar activity in the near term, preserving premium pricing.
• Pipeline Drugs: Several oral and subcutaneous agents in late-stage development might dilute market share.
• Regulatory Advances: Potential approvals for indications like primary progressive MS could expand the addressable market.

Summary of financial outlook

In the short term, KESIMPTA's revenues are expected to grow at approximately 40-50% annually through 2025, driven by expanding indications, geographic penetration, and increased patient acceptance of subcutaneous administration. Long-term growth will depend on competitive responses, patent exclusivity, and the lifecycle management of the molecule.

Key Takeaways

• KESIMPTA has a niche advantage with subcutaneous administration and competitive pricing but faces market share challenges from longstanding therapies.
• Market growth hinges on reimbursement policies, prescriber acceptance, and global regulatory progress.
• Revenue projections show substantial growth potential, contingent on sustained adoption and market expansion.

FAQs

1. What are the main clinical advantages of KESIMPTA over competitors?
It offers a weekly subcutaneous injection with a safety profile similar or superior to IV anti-CD20 agents, improving patient convenience and adherence.

2. How long will KESIMPTA's patent protection last?
Patent expiry is expected around 2030, with potential for extension through licensing or new indications.

3. Are biosimilars a threat to KESIMPTA?
Probably in the next 3-5 years, as biosimilar development progresses, though currently limited biosimilar alternatives exist.

4. What potential outside MS could expand KESIMPTA's market?
Research is ongoing for autoimmune diseases like rheumatoid arthritis and neuromyelitis optica, which could enlarge its indications.

5. How does payer coverage influence KESIMPTA sales?
Coverage policies strongly impact patient access; favorable reimbursement facilitates higher utilization, especially in cost-sensitive markets.

---

References

[1] Novartis. (2022). KESIMPTA (ofatumumab) label. U.S. Food and Drug Administration.
[2] IQVIA. (2022). Global Multiple Sclerosis Market Report.
[3] FDA. (2020). KESIMPTA approval announcement.
[4] European Medicines Agency. (2022). KESIMPTA product information.